CytoCorp (Chicago) reported that it is changing its name to CytoCore. The company's board approved the name change during its January meeting. The company will be "doing business as" CytoCore Inc. until the name is officially ratified by a vote of the shareholders at the annual shareholders meeting.
The company will continue to operate with the same stock symbol, MCDG.OB, until the shareholders meeting, at which time a new symbol will be acquired.
CytoCore develops bio-molecular cancer-screening systems, which can be utilized in a laboratory or at the point of care to assist in the early detection of cervical, uterine, gastrointestinal and other cancers.
Its InPath System is being developed to provide medical practitioners with an accurate, low-cost, cervical cancer-screening system that can be integrated into existing medical models or at the point of care.